ABT Abbott Laboratories
- Official Name: ABBOTT LABORATORIES
- Headquarters: 100 Abbott Park Road, Abbot Park, ABBOTT PARK, IL, 60064-3500 US
- CEO: Robert B. Ford
- Website: abbott.com
- Key Investor: VANGUARD GROUP INC | 9.76%
- Dedicated Investor: LIVELSBERGER FINANCIAL ADVISORY | 18.05%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-18 | 1 | Won by 4.187 | (0.439) - (4.626) | ||
| 2025-07-25 | 2 | Won by 0.183 | 5.124 - 4.941 | ||
| 2025-07-29 | 2R | Won by 1.756 | 1.374 - (0.382) | ||
| 2025-08-01 | 3 | Won by 1.605 | 1.056 - (0.549) | ||
| 2025-08-07 | 1R | Won by 0.808 | 0.706 - (0.102) | ||
| 2025-08-08 | 4 | Won by 0.106 TOTW | 5.190 - 5.084 | ||
| 2025-08-12 | 3R | Lost by 3.119 | (0.449) - 2.670 | ||
| 2025-08-15 | 5 | Won by 0.716 | (0.486) - (1.202) | ||
| 2025-08-20 | 1R | Lost by 0.942 | 0.688 - 1.630 | ||
| 2025-08-21 | 2R | Won by 0.277 | (0.992) - (1.269) | ||
| 2025-08-22 | 6 | Won by 4.274 | 3.923 - (0.351) | ||
| 2025-08-29 | 7 | Lost by 1.060 | 0.051 - 1.111 | ||
| 2025-09-04 | 3R | Won by 4.179 | 0.480 - (3.699) | ||
| 2025-09-05 | 8 | Won by 1.554 | 0.255 - (1.299) | ||
| 2025-09-11 | 4R | Won by 0.595 | 2.494 - 1.899 | ||
| 2025-09-12 | 9 | Lost by 0.672 | 0.597 - 1.269 | ||
| 2025-09-18 | 5R | Lost by 1.566 | 0.329 - 1.895 | ||
| 2025-09-19 | 10 | Lost by 0.067 | 1.743 - 1.810 | ||
| 2025-09-26 | 11 | Lost by 3.738 | (1.807) - 1.931 | ||
| 2025-10-03 | 12 | Lost by 1.946 | 0.718 - 2.664 | ||
| 2025-10-10 | 13 | Lost by 3.879 | (1.471) - 2.408 | ||
| 2025-10-17 | 14 | Lost by 3.493 | (2.675) - 0.818 | ||
| 2025-10-24 | 15 | Lost by 1.242 | (1.279) - (0.037) |
Latest News

How Big Could BSX Stock's Next Fall Be?
Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback oc...

Global Remote Cardiac Monitoring Market Size, Share & Trends Analysis 2026-2036 Featuring Profiles of Medtronic, Abbott Labs, Boston Scientific, GE HealthCare Technologies, Philips, Baxter International (Hillrom) and Other Key Players
Growth is driven by rising cardiovascular disease, telehealth adoption, and advances in wearable ECG devices, implantable monitors, AI analytics, and ...

Best Dividend Aristocrats For October 2026
The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Check out the Aristocrats ...

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporti...

Best Dividend Kings: September 2026
Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.

NVST vs. ABT: Which Stock Is the Better Value Option?
NVST vs. ABT: Which Stock Is the Better Value Option?

How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks
Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversificationâread ...

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note
Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.

Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery
Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the...

TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision ...